Reviva Pharmaceuticals Holdings Stock Probability of Future Stock Price Finishing Over 1.24
| RVPH Stock | USD 1.24 0.02 1.64% |
Reviva |
Reviva Pharmaceuticals Target Price Odds to finish over 1.24
The tendency of Reviva Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.24 | 90 days | 1.24 | about 36.94 |
Based on a normal probability distribution, the odds of Reviva Pharmaceuticals to move above the current price in 90 days from now is about 36.94 (This Reviva Pharmaceuticals Holdings probability density function shows the probability of Reviva Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Reviva Pharmaceuticals Holdings has a beta of -0.93 indicating Additionally Reviva Pharmaceuticals Holdings has an alpha of 0.4636, implying that it can generate a 0.46 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Reviva Pharmaceuticals Price Density |
| Price |
Predictive Modules for Reviva Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Reviva Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Reviva Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Reviva Pharmaceuticals is not an exception. The market had few large corrections towards the Reviva Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Reviva Pharmaceuticals Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Reviva Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.46 | |
β | Beta against Dow Jones | -0.93 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | 0.04 |
Reviva Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Reviva Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Reviva Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Reviva Pharmaceuticals is way too risky over 90 days horizon | |
| Reviva Pharmaceuticals may become a speculative penny stock | |
| Reviva Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Reviva Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reviva Pharmaceuticals Holdings currently holds about 23.19 M in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.13. | |
| Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: RVPH Year-End OLE Update |
Reviva Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Reviva Stock often depends not only on the future outlook of the current and potential Reviva Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Reviva Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.9 M |
Reviva Pharmaceuticals Technical Analysis
Reviva Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Reviva Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Reviva Pharmaceuticals Holdings. In general, you should focus on analyzing Reviva Stock price patterns and their correlations with different microeconomic environments and drivers.
Reviva Pharmaceuticals Predictive Forecast Models
Reviva Pharmaceuticals' time-series forecasting models is one of many Reviva Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Reviva Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Reviva Pharmaceuticals
Checking the ongoing alerts about Reviva Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Reviva Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Reviva Pharmaceuticals is way too risky over 90 days horizon | |
| Reviva Pharmaceuticals may become a speculative penny stock | |
| Reviva Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Reviva Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reviva Pharmaceuticals Holdings currently holds about 23.19 M in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.13. | |
| Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: RVPH Year-End OLE Update |
Check out Reviva Pharmaceuticals Backtesting, Reviva Pharmaceuticals Valuation, Reviva Pharmaceuticals Correlation, Reviva Pharmaceuticals Hype Analysis, Reviva Pharmaceuticals Volatility, Reviva Pharmaceuticals History as well as Reviva Pharmaceuticals Performance. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.